159 patents
Page 2 of 8
Utility
MULTISPECIFIC BINDERS OF TGFBeta-SUPERFAMILY LIGANDS AND USES THEREOF
24 Nov 22
In certain aspects, the disclosure provides multispecific binders (e.g., ActRIIA:TβRII heteromultimers comprising an ActRIIA polypeptide and a TfiRU polypeptide).
Ravindra Kumar, Dianne S. Sako, Roselyne Castonguay, Tzu-Hsing Kuo
Filed: 2 May 19
Utility
Compositions and methods for treating pulmonary hypertension
15 Nov 22
In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications.
Ravindra Kumar, John Knopf
Filed: 4 Jun 21
Utility
Methods for treatment of Duchenne muscular dystrophy with follistatin polypeptides
15 Nov 22
The disclosure provides, in part, follistatin polypeptides that are suitable for use in local administration and methods for use.
Ravindra Kumar, Asya Grinberg
Filed: 30 Jul 20
Utility
ALK7 Binding Proteins and Uses Thereof
3 Nov 22
This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins.
John Knopf, Ravindra Kumar, Asya Grinberg, Dianne Sako, Roselyne Castonguay, Yossi Dagon, Jonathan Belk, Nathan J. Sharkey
Filed: 29 May 20
Utility
Methods for Treating Myeloproliferative Disorders
20 Oct 22
In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder.
Ravindra Kumar, Rajasekhar Naga Venkata Sai Suragani
Filed: 24 Nov 21
Utility
Activin-ActRII antagonists and uses for treating anemia
18 Oct 22
Provided herein are methods for the treatment in a subject of anemia, anemia requiring RBC transfusion, low or intermediate-1-risk myelodysplastic syndromes (MDS), and/or non-proliferative chronic myelomonocytic leukemia (CMML) in any mammals wherein the methods comprise administration of Activin-ActRII signaling inhibitors to a subject in need of the treatment.
Kenneth M. Attie, Christopher Rovaldi, Abderrahmane Laadem
Filed: 3 Dec 15
Utility
Variant Actriib Proteins and Uses Thereof
29 Sep 22
In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of red blood cells or a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue.
Ravindra Kumar, Asya Grinberg, Erik M. Vogan
Filed: 7 Mar 22
Utility
ALK1 Receptor and Ligand Antagonists and Uses Thereof
22 Sep 22
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders.
Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra
Filed: 9 Dec 21
Utility
ALK7 Antagonists and Uses Thereof
15 Sep 22
In certain aspects, the disclosure provides ALK7 antagonists.
John Knopf, Ravindra Kumar, Asya Grinberg, Robert Scott Pearsall, Dianne S. Sako, Roselyne Castonguay, Gang Li, Yossi Dagon
Filed: 19 Oct 21
Utility
TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
13 Sep 22
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family.
Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay
Filed: 5 Oct 17
Utility
Variants Derived from Actriib and Uses Therefor
8 Sep 22
In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue.
John Knopf, Jasbir Seehra, Ravindra Kumar
Filed: 19 Jan 22
Utility
Compositions and Method for Treating Kidney Disease
18 Aug 22
In some aspects, the disclosure relates to activin and/or GDF antagonists and methods of using activin and/or GDF antagonists to treat, prevent, or reduce the progression rate and/or severity of kidney disease, particularly treating, preventing or reducing the progression rate and/or severity of one or more kidney disease-associated complications.
Ravindra KUMAR, Gang LI
Filed: 4 Oct 17
Utility
ALK4:ACTRIIB Heteromultimers and Uses Thereof
4 Aug 22
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells.
Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
Filed: 8 Feb 22
Utility
Actrii-binding Proteins and Uses Thereof
4 Aug 22
This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins.
Ravindra Kumar, Jonathan Belk, Asya Grinberg, Dianne Sako, Roselyne Castonguay
Filed: 29 May 20
Utility
Methods for Increasing Red Blood Cell Levels and Treating Ineffective Erythropoiesis
28 Jul 22
In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in a subject in need thereof.
Ravindra Kumar, Pedro Martinez, Rajasekhar Naga Venkata Sai Suragani
Filed: 16 Aug 21
Utility
Antagonists of Activin-actriia and Uses for Increasing Red Blood Cell Levels
30 Jun 22
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
Filed: 5 Aug 21
Utility
Activin-actrii Antagonists and Uses for Increasing Red Blood Cell Levels
30 Jun 22
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Matthew L. Sherman
Filed: 5 Aug 21
Utility
Truncated Actriib-fc Fusion Proteins
2 Jun 22
In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.
Jasbir Seehra, Ravindra Kumar
Filed: 25 Jun 21
Utility
Methods and Compositions for Treating Ulcers
5 May 22
The present disclosure provides compositions and methods for treating or preventing ulcers in subjects having low red blood cell levels and/or hemoglobin levels (e.g, anemia).
Kenneth M. Attie
Filed: 29 Oct 21
Utility
Compositions and methods for treating pulmonary hypertension
3 May 22
In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications.
Ravindra Kumar, John Knopf
Filed: 4 Jun 21